<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17673" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anti-NMDAR Encephalitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samanta</surname>
            <given-names>Debopam</given-names>
          </name>
          <aff>University of Arkansas for Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lui</surname>
            <given-names>Forshing</given-names>
          </name>
          <aff>CA Northstate Uni, College of Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Debopam Samanta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Forshing Lui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17673.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Anti NMDAR encephalitis is a relatively common autoimmune encephalitis characterized by complex neuropsychiatric features and the presence of Immunoglobulin G (IgG) antibodies against the NR1 subunit of the NMDA receptors in the central nervous system (CNS). It is the best known and likely the most common type of immune-mediated limbic encephalitis. Acute or subacute neuropsychiatric symptoms are the most common presenting features. Early diagnosis and prompt immunotherapy treatment can be beneficial for the outcome. This activity reviews the evaluation and management of anti-NMDAR encephalitis and highlights the role of the healthcare team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of anti-NMDAR encephalitis.</p></list-item><list-item><p>Review the evaluation of anti-NMDAR encephalitis.</p></list-item><list-item><p>Summarize the treatment and management options available for anti-NMDAR encephalitis.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance anti-NMDAR encephalitis to improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17673&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17673">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17673.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Anti NMDA Receptor encephalitis is an autoimmune encephalitis characterized by complex neuropsychiatric features and the presence of Immunoglobulin G(IgG) antibodies against the NR1 subunit of the NMDA receptors in the central nervous system(CNS). These antibodies are identifiable in the serum or the cerebrospinal; fluid (CSF).<xref ref-type="bibr" rid="article-17673.r1">[1]</xref></p>
      </sec>
      <sec id="article-17673.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>This autoimmune encephalitis develops due to the formation and attachment of IgG, particularly IgG1 and G3, to NMDA receptor (NR1) subunit with subsequent internalization of NMDA (glutamate) receptors, reduction of neuronal Ca influx, and decrease in the receptor-dependent synaptic currents.<xref ref-type="bibr" rid="article-17673.r2">[2]</xref>&#x000a0;In some patients, antibody production becomes triggered by associated ovarian teratoma and rarely other tumors. Viral encephalitis, particularly Herpes Simplex Virus encephalitis, can correlate with NMDAR antibody production over the&#x000a0;ensuing three weeks with subsequent development of autoimmune encephalitis.<xref ref-type="bibr" rid="article-17673.r3">[3]</xref> In&#x000a0;most cases, the exact etiology of antibody production remains unknown, however, regardless of the origin, the pathogenesis leads to a superfluous production of autoantibodies by intrathecal plasma cells.</p>
      </sec>
      <sec id="article-17673.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Although this is a rare disease (one affected out of 1.5 million people per year), anti NMDAR encephalitis is the best known and probably the most common autoimmune encephalitis.<xref ref-type="bibr" rid="article-17673.r4">[4]</xref> In the California Encephalitis Project, the incidence of anti NMDAR encephalitis was higher than the incidence of any individual viral encephalitis.<xref ref-type="bibr" rid="article-17673.r5">[5]</xref> There have been reports of anti NMDAR encephalitis has been reported in infants of 2 months of age to up to an advanced age of 85 years old. Females are afflicted four times more commonly. Young adult females between 25 and 35 years of age are most commonly affected.</p>
      </sec>
      <sec id="article-17673.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Autoimmune encephalitis was classified in the past as paraneoplastic or non-paraneoplastic, depending on whether there are any identifiable tumor-associated antibodies. These paraneoplastic antibodies included anti-neuronal nuclear antibody type 1 (anti-Hu), anti-Ri, or Yo, etc. With a better understanding of the pathophysiology of different auto-immune encephalitis, the&#x000a0;more nuanced&#x000a0;way of classification is pathophysiologically based. The modern-day classification is to classify the immune encephalitis according to the targets of the antibodies. The classical paraneoplastic encephalitis, as named above, is mediated through a predominant T-cell mediated mechanism with cytotoxic T cells demonstrated in the pathological specimens.&#x000a0;These immune responses are the result of molecular mimicry between the neuronal tissue antigen and tumor antigens. The antibodies themselves are not pathogenic. These antibodies direct their activity towards intracellular constituents. The other class of autoimmune encephalitis consists of antibodies directed against synaptic or cell-surface antigens such as anti-NMDAR, anti-GAD, anti-VGKC antibody-mediated encephalitides. These are real antibody or B-cell mediated autoimmune encephalitis with real pathogenic antibodies.<xref ref-type="bibr" rid="article-17673.r6">[6]</xref>&#x000a0;Anti-NMDAR antibody immune encephalitis is a B-cell mediated autoimmune encephalitis with an actual pathogenic antibody that can be removed by plasma exchange resulting in improvement of the underlying pathology.</p>
      </sec>
      <sec id="article-17673.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Presentation of anti NMDAR encephalitis has been categorized into five distinct phases: prodromal phase, psychotic phase, unresponsive phase, hyperkinetic phase, and recovery phase.<xref ref-type="bibr" rid="article-17673.r7">[7]</xref></p>
        <p>&#x000a0;The disease starts with a prodromal state mimicking common viral infections. But within weeks to a few months(less than 3 months), complex neuropsychiatric features emerge rapidly during the psychotic phase. Presenting clinical features may be different between children and adults. Adults usually present with psychiatric symptoms compared with movement disorders or seizures as the most common presentation in children. Acute or subacute behavioral symptoms are the most common presenting features in adult patients. Though there is no specific psychiatric phenotype, variable positive and negative psychiatric symptoms such as visual or auditory hallucination, acute schizoaffective episodes, depression, mania, and addictive or eating disorders can appear rapidly within days to weeks in these patients with no prior psychiatric diagnosis. The onset occurs fairly quickly in contrast to the slow progression noted in primary psychiatric diseases. Many patients get admitted to the psychiatric inpatient unit due to severe presentation and spend weeks for symptomatic management. Although several patients would have coexistent neurological features at the onset, some may develop within a few weeks of presentation. Importantly, some patients are intolerant to neuroleptics and can develop hyperthermia, muscle rigidity, rhabdomyolysis, or coma after exposure to neuroleptics.</p>
        <p>In contrast to more prevalent positive symptoms in schizophrenia, anti-NMDAR encephalitis patients have both positive and negative symptoms. Besides a diverse range of neuropsychiatric symptoms- apathy, anxiety, fluctuating sensorium, bizarre behaviors, hypersexuality, wandering, &#x000a0;aphasia, amnesia, apraxia, sleep-wake cycle disruption with severe insomnia, delusion- many patients, particularly children and male adults, present with seizures, both focal and generalized seizures. Seizures can be resistant to antiepileptic drugs(AEDs) and may evolve to status epilepticus or even refractory status epilepticus. The psychotic phase evolves into the unresponsive phase characterized by mutism, decreased motor activity, and catatonia. Following the unresponsive phase, a hyperkinetic phase with autonomic instability and prominent movement disorders becomes evident. In the presence of notable autonomic disruption - labile blood pressures and heart rates, cardiac arrhythmias, temperature instability, and central hypoventilation- some patients require admission to the ICU and in some instances, use of mechanical ventilation and cardiac pacemaker. The classic movement disorder in this phase is oro-lingual dyskinesias with lip-smacking, tongue protrusion, jaw movements, but a diverse range of movement disorders can present in this phase, such as automatisms, dyskinesia, dystonia, and choreoathetosis, myorhythmia, blepharospasm, oculogyric crisis, and hemiballismus. With adequate immunotherapy and supportive care, the patients may enter the recovery phase after months of treatment. Recovery of language function and behavioral symptoms occurs at the end.</p>
        <p>Rarely, anti-NMDAR encephalitis patients develop demyelinating disorders such as neuromyelitis optica spectrum disorder- concurrently, preceding or following the encephalitis- with disease-specific antibody production(aquaporin-4 or myelin oligodendrocyte glycoprotein).<xref ref-type="bibr" rid="article-17673.r8">[8]</xref></p>
      </sec>
      <sec id="article-17673.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Routine laboratory testing is usually nonspecific. Anti NMDAR IgG antibodies, detected by indirect immunofluorescence assay in the serum and the CSF, are diagnostic for the disease. Antibody titers are higher in the CSF, and in some cases, diagnosis is possible after CSF testing with concurrent negative serum reports. CSF also can have low-grade hypercellularity and oligoclonal bands.<xref ref-type="bibr" rid="article-17673.r1">[1]</xref> Brain MRI can be normal, but nonspecific white and gray matter T2/FLAIR&#x000a0; signal hyperintensity can be present, most commonly in the hippocampus. Diffusion restriction positivity has been reported, as well as cerebellar atrophy, as the only irreversible radiologic finding with this encephalitis.<xref ref-type="bibr" rid="article-17673.r9">[9]</xref></p>
        <p>&#x000a0;One specific interictal EEG finding is extreme delta brushes(bursts of beta activity superimposed on diffuse delta activities)- a finding commonly seen in healthy premature neonates. Other EEG abnormalities- generalized theta and delta slowing, subclinical seizures, nonconvulsive status epilepticus- are frequently present but nonspecific findings of encephalopathy or encephalitis. After confirmation of the diagnosis, a comprehensive evaluation should be done to detect underlying malignancy. Whole-body CT, MRI abdomen and transvaginal ultrasound are commonly employed to detect tumors. Transvaginal ultrasonography is the most crucial test for young women presenting with the illness due to the high incidence of underlying ovarian teratoma. If these tests are unrevealing, PET scans and exploratory laparotomy are options.<xref ref-type="bibr" rid="article-17673.r10">[10]</xref>&#x000a0;In cases of negative initial screening, follow-up MRI abdomen and pelvis should be repeated every six months for at least four years.<xref ref-type="bibr" rid="article-17673.r11">[11]</xref></p>
      </sec>
      <sec id="article-17673.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Early diagnosis and treatment can be beneficial for the final outcome.<xref ref-type="bibr" rid="article-17673.r1">[1]</xref>&#x000a0;Prompt treatment can be initiated before the final diagnosis in case of a reasonable degree of suspicion after collecting serum and CSF samples for confirmation of autoimmune encephalitis.<xref ref-type="bibr" rid="article-17673.r12">[12]</xref> Expeditious immunomodulatory/immunosuppressive therapies with corticosteroids, immunoglobulin infusion(IVIG), and plasmapheresis (PLEX) are first-line therapies, as well as tumor removal if applicable, with robust supportive therapies.<xref ref-type="bibr" rid="article-17673.r13">[13]</xref><xref ref-type="bibr" rid="article-17673.r14">[14]</xref></p>
        <p>However, which of these immunotherapies should start first, and if combination therapy should be used from the beginning has not been researched in a controlled fashion. Additionally, for sequential therapies, the optimal order of therapies has not been standardized. PLEX has been utilized more frequently in the beginning due to its ability to quickly remove the autoantibodies, and recent retrospective studies suggested PLEX therapy before IVIG administration may improve outcomes. Unfortunately, only approximately half of the patients would respond to first-line therapy. Rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil have been used as&#x000a0;second-line therapies if clinical improvement does not occur after four weeks of treatment with first-line therapy. Some experts recommended the use of rituximab early in the disease process as first-line therapy. For refractory patients, bortezomib(proteasome inhibitor), alemtuzumab(humanized monoclonal antibody against CD52), intrathecal methotrexate, and tocilizumab(a monoclonal antibody against interleukin-6 receptor) can work in a small number of patients with success.</p>
        <p>Seizure management in the acute phase can be difficult and requires AEDs along with immunotherapy. However, these patients do not develop epilepsy as the seizure improves with the improvement of encephalitis. A retrospective series reported that valproate, levetiracetam, and carbamazepine had been similarly effective, but carbamazepine was associated with fewer side effects.<xref ref-type="bibr" rid="article-17673.r15">[15]</xref>&#x000a0;Gradual reduction of AEDs is possible during follow-up, and most can be discontinued in 2 years without seizure recurrence. Antipsychotic agents are frequently used to treat behavioral symptoms, but neuroleptic malignant syndrome can occur.<xref ref-type="bibr" rid="article-17673.r16">[16]</xref>&#x000a0;Benzodiazepines and electroconvulsive therapy have been utilized to treat catatonia. Abnormal movements associated with this encephalitis are challenging to control and require a high dose of sedative medications, botulinum toxin, or tetrabenazine.ICU management is essential during the severe phase of the disease for several reasons: airway protection, altered cognition, dyskinesias, seizures, abnormal behavior, temperature instability, heart rate variability, and arrhythmia.<xref ref-type="bibr" rid="article-17673.r17">[17]</xref></p>
        <p>Herpes simplex encephalitis is the commonest sporadic encephalitis. Any patient who presented with clinical features of acute encephalitis should be treated empirically with IV acyclovir, pending the result of HSV PCR results. Acyclovir will be continued or stopped depending on the outcome of the PCR test. It is essential to recognize the fact that early recurrence of HSV encephalitis within 2&#x000a0;to 3 weeks of the encephalitis is often due to anti-NMDAR encephalitis triggered by the viral encephalitis. It is reasonable and understandable that HSV is a neurotropic virus with predominant involvement of the limbic gray matter, which has a high concentration of NMDA receptors. The viral infection may lead to a higher likelihood of release of the receptor and subsequent antibody formation and secondary immune encephalitis.</p>
      </sec>
      <sec id="article-17673.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Another autoimmune encephalitis</p>
          </list-item>
          <list-item>
            <p>Primary psychiatric disorder</p>
          </list-item>
          <list-item>
            <p>Viral encephalitis</p>
          </list-item>
          <list-item>
            <p>Neuroleptic malignant syndrome</p>
          </list-item>
          <list-item>
            <p>Catatonia</p>
          </list-item>
          <list-item>
            <p>Acute disseminated encephalomyelitis</p>
          </list-item>
          <list-item>
            <p>Mitochondrial encephalitis</p>
          </list-item>
          <list-item>
            <p>Cerebral space-occupying lesions</p>
          </list-item>
          <list-item>
            <p>Exposure to&#x000a0;drugs, toxins, or withdrawal symptoms</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17673.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>There are some independent predictors of worse outcomes: requirement of ICU stay, treatment delay over four weeks,&#x000a0;no improvement after four weeks of treatment, abnormal brain MRI, and white blood cell greater than 20 cells/microL. All these variables can be given one point each to form a functional score. A higher score is associated with poor functional status at one year from the disease onset, but this should not be used to guide therapy or determine the final prognosis as one-third of the patients with poor functional status at one year may improve at two years.<xref ref-type="bibr" rid="article-17673.r18">[18]</xref></p>
      </sec>
      <sec id="article-17673.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Overall, 20% of patients develop focal deficits or die from the anti NMDAR encephalitis. Approximately 10% of patients may relapse within two years of initial presentation but usually with a less severe presentation.<xref ref-type="bibr" rid="article-17673.r13">[13]</xref>&#x000a0;More commonly reported long-term deficits involve attention, memory, and executive functions.</p>
      </sec>
      <sec id="article-17673.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with suspected&#x000a0;anti-NMDAR encephalitis should have a lumbar puncture and antibody testing on CSF. The initiation&#x000a0;of immunotherapy should not delay while waiting for antibody results.&#x000a0;</p>
      </sec>
      <sec id="article-17673.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of autoimmune encephalitis are very complex and best done with an interprofessional team. The diagnosis usually requires consultation from a neurologist.&#x000a0;</p>
        <p>The treatment approach of immunotherapy is the prompt initiation of first-line treatment (corticosteroids, intravenous immunoglobulins, or plasma exchange) and escalation to second-line therapies(rituximab, cyclophosphamide) if needed. Because some patients have neuropsychiatric features, a mental health nurse should be involved in the care. The pharmacist should educate the patient and caregivers about the drugs, their adverse effects, and potential benefits, as well as performing medication reconciliation and dose verification. Nursing will provide follow-up, answer patient questions, and monitor therapeutic effectiveness as well as adverse events, reporting any issues to the treating clinician. The recovery is slow, and hence social work should be involved to ensure that the patient has adequate support services. Those who develop movement disorders may have difficulty with speech, gait, and swallowing. Long-term monitoring by the interprofessional team is vital to prevent high morbidity. [Level 5]</p>
      </sec>
      <sec id="article-17673.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17673&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17673">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/anti-nmdar-encephalitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17673">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17673/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17673">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17673.s15">
        <fig id="article-17673.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Clues to diagnose anti NMDAR encephalitis in patients presenting with new acute onset of psychosis. Contributed by Ritika Agarwal, Adapted from Dalmua et al 2019</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Slide1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17673.s16">
        <fig id="article-17673.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Table describing the proposed therapy for treatment of Anti NMDAR encephalitis along with dosage. Contributed by Ritika Agarwal, Adapted from Remy et al (2017)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="WINWORD_5mQWPqYtPT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17673.s17">
        <title>References</title>
        <ref id="article-17673.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gleichman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dessain</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.</article-title>
            <source>Lancet Neurol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1091</fpage>
            <page-range>1091-8</page-range>
            <pub-id pub-id-type="pmid">18851928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gleichman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tsou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.</article-title>
            <source>J Neurosci</source>
            <year>2010</year>
            <month>Apr</month>
            <day>28</day>
            <volume>30</volume>
            <issue>17</issue>
            <fpage>5866</fpage>
            <page-range>5866-75</page-range>
            <pub-id pub-id-type="pmid">20427647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spatola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vlagea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mattozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>C&#x000e1;rceles-Cordon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Heras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Llufriu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muchart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Erro</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abraira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monros-Gim&#x000e9;nez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corral-Corral</surname>
                <given-names>&#x000cd;</given-names>
              </name>
              <name>
                <surname>Montejo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Secondi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Juan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <collab>Spanish Herpes Simplex Encephalitis Study Group</collab>
            </person-group>
            <article-title>Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>760</fpage>
            <page-range>760-772</page-range>
            <pub-id pub-id-type="pmid">30049614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Planagum&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radosevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mannara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models.</article-title>
            <source>Lancet Neurol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1045</fpage>
            <page-range>1045-1057</page-range>
            <pub-id pub-id-type="pmid">31326280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gable</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sheriff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tilley</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>899</fpage>
            <page-range>899-904</page-range>
            <pub-id pub-id-type="pmid">22281844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Coevorden-Hameete</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>de Graaff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hoogenraad</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Detection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous System.</article-title>
            <source>Front Mol Neurosci</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">27303263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ide</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Monzen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshii</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iigaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>Feb</month>
            <day>12</day>
            <volume>70</volume>
            <issue>7</issue>
            <fpage>504</fpage>
            <page-range>504-11</page-range>
            <pub-id pub-id-type="pmid">17898324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ftberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cellucci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Irioka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cobo Calvo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Overlapping demyelinating syndromes and anti&#x02013;N-methyl-D-aspartate receptor encephalitis.</article-title>
            <source>Ann Neurol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>411</fpage>
            <page-range>411-28</page-range>
            <pub-id pub-id-type="pmid">24700511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tominaga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Someko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oguni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanazawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.</article-title>
            <source>JAMA Neurol</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>706</fpage>
            <page-range>706-13</page-range>
            <pub-id pub-id-type="pmid">27111481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lagarde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lepine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caietta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boucraut</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chabrol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Milh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guedj</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Cerebral (18)FluoroDeoxy-Glucose Positron Emission Tomography in paediatric anti N-methyl-D-aspartate receptor encephalitis: A case series.</article-title>
            <source>Brain Dev</source>
            <year>2016</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>461</fpage>
            <page-range>461-70</page-range>
            <pub-id pub-id-type="pmid">26542469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staley</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jamy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Figge</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>N-Methyl-d-aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and Management.</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>16</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-142</page-range>
            <pub-id pub-id-type="pmid">30134661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breese</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Apiwattanakul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Anti-N-methyl-D-aspartate receptor encephalitis: early treatment is beneficial.</article-title>
            <source>Pediatr Neurol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-4</page-range>
            <pub-id pub-id-type="pmid">20159432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gabilondo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honig</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Benseler</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gresa-Arribas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ryan-Florance</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.</article-title>
            <source>Lancet Neurol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-65</page-range>
            <pub-id pub-id-type="pmid">23290630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shuang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.</article-title>
            <source>Epilepsy Behav</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>68</volume>
            <fpage>57</fpage>
            <page-range>57-65</page-range>
            <pub-id pub-id-type="pmid">28109991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Bruijn</surname>
                <given-names>MAAM</given-names>
              </name>
              <name>
                <surname>van Sonderen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Coevorden-Hameete</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Bastiaansen</surname>
                <given-names>AEM</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MWJ</given-names>
              </name>
              <name>
                <surname>Rouhl</surname>
                <given-names>RPW</given-names>
              </name>
              <name>
                <surname>van Donselaar</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Majoie</surname>
                <given-names>MHJM</given-names>
              </name>
              <name>
                <surname>Neuteboom</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PAE</given-names>
              </name>
              <name>
                <surname>Thijs</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA<sub>B</sub>R encephalitis.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>May</month>
            <day>07</day>
            <volume>92</volume>
            <issue>19</issue>
            <fpage>e2185</fpage>
            <page-range>e2185-e2196</page-range>
            <pub-id pub-id-type="pmid">30979857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2019</year>
            <volume>15</volume>
            <fpage>773</fpage>
            <page-range>773-778</page-range>
            <pub-id pub-id-type="pmid">31040676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neyens</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Gaskill</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Chalela</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Critical Care Management of Anti-N-Methyl-D-Aspartate Receptor Encephalitis.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>1514</fpage>
            <page-range>1514-1521</page-range>
            <pub-id pub-id-type="pmid">29927776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17673.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>e244</fpage>
            <page-range>e244-e252</page-range>
            <pub-id pub-id-type="pmid">30578370</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
